Ever Supreme Bio Technology Co

Ever Supreme Bio Technology Co EPS

The Earnings per Share (EPS) of Ever Supreme Bio Technology Co (6712.TWO) as of Oct 29, 2026 is 4.90 TWD. In the previous year, Earnings per Share (EPS) was 4.55 TWD — a change of 7.83% (higher).

EPS

4.90TWD

YoY

7.83%

Last updated:

Earnings per Share (EPS) of Ever Supreme Bio Technology Co is 2025 4.90 TWD. Earnings per Share (EPS) of Ever Supreme Bio Technology Co was 2024 4.55 TWD. It decreases by 7.83% higher compared to the previous year.

The Ever Supreme Bio Technology Co EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2020
-1.58 TWD
Jan 1, 2021
4.91 TWD
Jan 1, 2022
2.66 TWD
Jan 1, 2023
7.22 TWD
Jan 1, 2024
4.55 TWD
Jan 1, 2025
4.90 TWD
Jan 1, 2026 (e)
5.33 TWD
Jan 1, 2027 (e)
5.73 TWD
The Ever Supreme Bio Technology Co EPS history
YEAREPSYoY
est5.73TWD+7.50%
est5.33TWD+8.72%
4.90TWD+7.83%
4.55TWD-37.02%
7.22TWD+171.09%
2.66TWD-45.77%
4.91TWD-411.66%
-1.58TWD+37.07%
-1.15TWD+28.80%
-0.89TWD+57.42%
-0.57TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ever Supreme Bio Technology Co Stock analysis

What does Ever Supreme Bio Technology Co do? Ever Supreme Bio Technology Co., Ltd. generates revenue through the research, development, and sale of stem cell products. The company's primary products include ADCV01, an autologous dendritic cell tumor vaccine currently in phase II clinical trials in Taiwan, and UMSC01, a human allogeneic umbilical cord stem cell product approved by the FDA for clinical phase I in the United States and undergoing similar trials in Taiwan for myocardial infarction treatment. UMSC01 is also being evaluated for acute ischemic stroke therapy in the United States under FDA phase I clinical trials. The firm targets medical institutions and healthcare providers in Taiwan and the United States for its stem cell therapies, focusing on cardiovascular and neurological conditions. The company's revenue streams are derived from the development and commercialization of its stem cell product pipeline, with ADCV01 and UMSC01 representing key assets in its portfolio. UMSC01's dual approval status in the U.S. and Taiwan positions it as a significant product for both markets. Ever Supreme Bio Technology plans to expand its offerings by developing mesenchymal stem cells for multiple sclerosis treatment, aiming to enter new therapeutic segments in the future. Ever Supreme Bio Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ever Supreme Bio Technology Co stock

Earnings per Share (EPS) of Ever Supreme Bio Technology Co is 4.90 TWD in 2025.

Earnings per Share (EPS) of Ever Supreme Bio Technology Co changed from 4.55 TWD to 4.90 TWD, representing a 7.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Ever Supreme Bio Technology Co since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Ever Supreme Bio Technology Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Ever Supreme Bio Technology Co